Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 1997

View Archived Issues

Company Profile: CV Therapeutics

Distribution agreement signed for periodontal tissue monitor kit

New prodrug approach claimed by Merck & Co.

Dopamine synthesis and release inhibitors discovered at AHP

Neurokinin antagonists in the pipeline at Schering-Plough

Anandamide amidase inhibitors reported in patent literature

U.S. patent issued for Sertoli cell technology

New discovery opens the way toward a potential new application for estrogen-like drugs

Lilly research leads to the discovery of new antiobesity compounds

Virus Research Institute: Q3 1997 highlights

GH secretagogues under development at Merck

New muscarinic acetylcholine receptor modulators from Novo Nordisk

Cortex/U. of California researchers disclose ampakine-like compounds

Therapeutics discovery collaboration formed by Ontogeny and ArQule

Forbes files IND to begin phase II trials of Cardiorex in primary hypercholesterolemia

U.K. launch for inhaled nicotine replacement therapy

New launches for Abelcet; The Liposome Co./Wyeth-Ayerst partnership broadened

Chiron's Proleukin recommended for approval for new indication

NeoPharm pursues FDA approval of Neomark following negative advisory committee decision

Biorex and Abbott sign definitive agreement for bimoclomol

Results from animal studies with OPC-14523 presented

Sustiva trials now open to more AIDS patients

Mechanism of antiparkinsonian activity of KW-6002 explored in mice

Efficacy of PR-000608 in mouse model of Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...